This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Events & Webinars

The management and treatment of patients with advanced unresectable hepatocellular carcinoma (HCC)

 Nexavar and Stivarga

Description

How do you manage and treat your patients with advanced unresectable HCC? Watch as experts Dr David Pinato and Dr Rohini Sharma discuss what they would consider in this educational video. See them talking about the evolving treatment landscape of advanced HCC, guidance on key treatment considerations and appropriate treatment selection for advanced HCC patients plus their recommendations for potentially maximising treatment benefits. Their discussion can be watched as a complete video and has also been divided into easy to watch, short clips below.


Speakers
    • dr_david_pinato
      Dr David Pinato

    Dr David Pinato is a Clinician Scientist and Consultant Medical Oncologist supported by the Wellcome Trust Strategic Fund (IPPRF scheme) working within the Department of Surgery and Cancer at Imperial College, London. Dr Pinato leads a translational research program focusing on the early clinical implementation of novel experimental anticancer therapies to the clinic, with particular emphasis on anti-cancer immunotherapy. He has led the inception of a portfolio of first-in-class studies of immune checkpoint inhibitors in liver cancer, which has represented David’s focus of research since graduation.

    • dr_rohini_sharma
      Dr Rohini Sharma

    Dr Rohini Sharma is a Reader in Clinical Pharmacology and Medical Oncology. She is also a Consultant Medical Oncologist based at the Hammersmith Hospital campus of Imperial College Healthcare NHS Trust. Her clinical and research interests are in HCC, Neuroendocrine tumours (NETs) and development of novel biomarkers. To this end, Dr Sharma is the Oncology lead for the specialist Hepato-Oncology Clinic, a unique service where patients are jointly managed by a Hepatologist and Medical Oncologist with a view to improving clinical outcomes and promoting research. She is the lead of the liver cancer research group at Imperial and also the Oncology lead for the management of NETs within the Trust.

Bayer Oncology HCC Clinical Expert Series
Nexavar® (sorafenib) | Stivarga® (regorafenib)
HCC Resources
Nexavar® (sorafenib) | Stivarga® (regorafenib)
Oncology Homepage
Welcome to the home of Bayer Oncology
PP-PF-ONC-GB-0398, February 2024

PP-NEX-GB-0212 | February 2024